Next Article in Journal
Galli–Galli Disease: A Comprehensive Literature Review
Previous Article in Journal
Direct Immunofluorescence of Skin and Oral Mucosa: Guidelines for Selecting the Optimum Biopsy Site
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Dermatopathology
Volume 11
Issue 1
10.3390/dermatopathology11010007
dermatopathology-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Histopathology of Leg Ulcers

by
Amun Georg Hofmann
1,
Julia Deinsberger
1,
André Oszwald
2 and
Benedikt Weber
1,*
1
Department of Dermatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria
2
Department of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Dermatopathology 2024, 11(1), 62-78; https://doi.org/10.3390/dermatopathology11010007
Submission received: 17 December 2023 / Revised: 22 January 2024 / Accepted: 23 January 2024 / Published: 29 January 2024
Browse Figures
Versions Notes

Abstract

:
Ulcerations of the lower extremities are a frequently encountered problem in clinical practice and are of significant interest in public health due to the high prevalence of underlying pathologies, including chronic venous disease, diabetes and peripheral arterial occlusive disease. However, leg ulcers can also present as signs and symptoms of various rare diseases and even as an adverse reaction to drugs. In such cases, correct diagnosis ultimately relies on histopathological examination. Apart from the macroscopic presentation, patient history and anatomic location, which are sometimes indicative, most ulcers have very distinct histopathological features. These features are found in different layers of the skin or even associated vessels. In this narrative review, we discuss and highlight the histopathological differences of several types of leg ulcers that can contribute to efficient and accurate diagnosis.

1. Introduction

The term leg ulcer, referring to chronic wounds on the lower extremities, does not constitute a diagnosis itself but reflects a symptom or long-term consequence of underlying diseases [1]. Precise epidemiological data are scarce, but the reported prevalence ranges between 0.18% and 2% in the European population and may affect between 3.6% and 5% of patients aged 65 years and older globally [2,3,4,5].
The most frequent etiologies are venous insufficiency (reported share among leg ulcers: 43–85%), arterial insufficiency (10–20%), diabetes (10–15%) and a combination of these (10–15%) [1,2,6,7,8,9]. However, there are at least 180 different reported causes of leg ulcerations. Among them are other vascular causes, vasculitides, other immunological and infectious diseases, malignant tumors and hematological disorders [2].
Diagnosis is often based on clinical and/or instrument-based data, but it can be challenging when the underlying etiology is unrelated to venous or arterial pathologies. The frequency of uncommon etiologies in leg ulcers is scientifically debated, ranging from 1 to 30% [10,11,12,13].
Leg ulcers that do not respond to standard wound therapy and exhibit atypical macroscopic features or clinical manifestations should be subject to a wound biopsy and histopathological examination [12,14,15,16]. The histopathological hallmark of ulcerations is the loss of the epidermis and of at least a part of the dermis, which can also affect subcutaneous tissue. In the course of the ulcerative process, the normal pattern of collagen bundles in the dermis is destroyed, resulting in scar tissue development [17]. Additional patterns and features, such as an immune cell infiltrates or specific vascular changes, can guide the diagnosis based on the histopathological picture [18].
This review comprehensively outlines the histopathological findings observed in various types of chronic leg ulcerations, aiding in the differential diagnosis of this significant cutaneous disorder.

2. Venous Leg Ulcers

Chronic venous disease (CVD) is the most frequent cause of leg ulcers, underlying 43–85% of all cases [6,7,17,19]. The underlying pathophysiology of CVD is a mismatch of venous pressure and unidirectional blood flow. Dilation of the vessel wall and consequent valvular incompetence lead to reflux, which promotes venous hypertension and thus establishes a vicious circle [20,21]. CVD is commonly classified by clinical manifestation according to the CEAP system, comprising six classes (C1–C6). C6 is the most severe class and is characterized by the presence of active venous leg ulcers (VLUs) [22], most frequently affecting the medial and anterior malleolus and the pretibial area [6]. Due to the frequency and characteristic macroscopic appearance of VLU, their histopathological examination is an exception. Guidelines suggest performing a biopsy only in case of atypical features or unresponsiveness to 4 to 6 weeks of wound and compression therapy [14,15,23].
The inflammatory infiltrates of VLU samples comprise macrophages, mast cells and lymphocytes. Interestingly, biopsies of non-ulcerated skin from CVD patients (without active ulcerations) also show increased dermal leukocyte infiltration in all stages of the disease, mostly macrophages and T-lymphocytes, suggesting perpetuated chronic skin inflammation in CVD [24,25]. The wound bed often contains necrotic tissue and/or insufficient granulation tissue [26]. The transition from a normal epidermis to an ulcer can be abrupt in VLUs, resulting in a so-called “step sign” [17]. Increased expression of the endothelial adhesion molecules ICAM-1, VCAM-1 and E-selectin has been shown at the border of the ulcer [27]. The remaining epidermis characteristically shows spongiosis, hyperkeratosis and acanthosis, and frequently observed dermal changes include diffuse edema, granulation tissue, fibrin, hemosiderophages, collagen bundle degeneration and fibrosis [17,28,29,30,31]. The appearance of pericapillary fibrin cuffs that incorporate laminin, fibronectin, tenascin, collagen and trapped leukocytes is highly characteristic of VLUs [29,32,33,34,35]. Microcirculatory dysfunction is reflected by dilated capillaries and a reduced capillary density, which has been shown to be negatively associated with VLU healing tendencies [27,35]. In the skin surrounding VLUs, lymphatic vessel density is increased. However, the vessels are more often collapsed, and the remaining patent vessels more often show open inter-endothelial junctions compared with healthy controls [36]. Impaired lymph flow may present as lymphangectasia and result in phlebolymphedema [17] (see Table 1, Figure 1).

2.1. Mixed Venous-Arterial Leg Ulcers

Leg ulcers with a mixed etiology are usually caused by a combination of venous insufficiency and other venous or arterial pathologies. Accordingly, most of these ulcers present with macro- and microscopical features of VLUs and additional characteristics of arterial ulcers, e.g., ischemic necrosis [6,17].

2.2. Livedoid Vasculopathy

Livedoid vasculopathy, formerly known as atrophie blanche due to characteristic porcelain-white scars [37], is a cutaneous disorder characterized by bilateral leg ulceration [38,39]. Its pathogenesis involves the focal non-inflammatory thrombosis of dermal veins and venulae in the subpapillary vascular plexus [39,40] that can usually be observed in histopathological examinations [41,42]. Other features include epidermal spongiosis or atrophy in the margin area, vessel wall thickening with endothelial proliferation, fibrinoid degeneration, fibrin deposits and fibrin thrombi in the lumen [38,39,43,44,45,46]. Subintimal hyalinization and the absence of perivascular inflammation are characteristic, even though secondary inflammatory changes may be observed in later stages [38,42,44,47] (see Table 2, Figure 2).

3. Arterial Leg Ulcers

3.1. Occlusive-Ischemic

Arterial leg ulcers develop due to an oxygen deficit in the tissue and are most commonly associated with peripheral artery disease (PAD) [1]. PAD is mainly caused by atherosclerotic narrowing of the arteries. Subsequent hemodynamic changes and macro- and microvascular adaptions, as well as tissue remodeling processes, impair blood supply, leading to end-organ ischemia [48]. The two most commonly used systems to classify the disease, Rutherford and Fontaine, are both based on clinical criteria. The most severe stage in both systems is based on tissue loss, as seen in ulcerations and gangrene [49]. PAD ulcers can primarily be found on the toes and plantar, presenting as demarcated lesions [50]. The wound bed tends to be dry, and necrotic areas might be macroscopically visible [30,51]. Histologically, they are highly associated with epidermal thinning and necrosis. In the dermis, thrombosed vessels and dermal sclerosis with potentially hyalinized areas can be observed [17] (see Table 3).

3.2. Ischemic Subcutaneous Arteriolosclerosis

Ischemic subcutaneous arteriolosclerosis describes several entities that share arteriolar calcification as one of their histopathological hallmarks. It includes proximal non-uremic calciphylaxis with normal renal and parathyroid function and proximal and distal calciphylaxis in patients with end-stage renal insufficiency, as well as the arteriolosclerotic ulcer of Martorell [1,52,53].

3.3. Arteriolosclerotic Ulcer of Martorell

The arteriolosclerotic ulcer of Martorell is typically located on the lateral side of the lower legs, characterized by disproportional pain, and it is strongly associated with arterial hypertension [54,55]. The most prominent histopathological features include media hypertrophy and progressive hyalinotic alteration of the arteriolar wall, leading to an increased wall–lumen ratio and subsequently resulting in luminal stenosis [52,56]. Additionally, arteriolar calcification can be seen in most cases [52,57,58]. Further described histopathological features include acanthosis, intimal hyperplasia, sub-endothelial hyalinosis, luminal thrombosis and necrosis [52,57,58,59,60,61,62]. The frequently observed periarteriolitis may occur as a non-specific cellular response to the surrounding necrosis [57,63] (see Table 4). Venous vessels are often severely damaged due to the inflammatory process and may develop thrombotic occlusions [64,65,66]. However, the specificity of these features is highly debated to be insufficient [57,67]. For example, it has been shown that cutaneous arteriolosclerosis is independently associated with age [68] (see Figure 3).

3.4. Calciphylaxis

Calciphylaxis is a calcifying vasculopathy of the small- and medium-sized blood vessels of the dermis and subcutis, which in turn leads to ischemia and necrosis of the affected skin areas [69]. Calciphylaxis is most frequently associated with chronic kidney failure and the related disturbance of calcium phosphate metabolism. However, there are also non-uremic causes such as hyperparathyroidism, malignancies or autoimmune diseases [70,71]. Its histopathological appearance is characterized by media calcification, endovascular fibrosis, intima hyperplasia and vascular thrombosis [72,73]. Additionally, ectopic calcium deposits can also be found in extravascular connective and adipose tissue [74] (see Table 5, Figure 4).

3.5. Diabetic Leg Ulcers

Diabetic patients combine multiple risk factors for the occurrence of lower extremity ulcers; diabetes itself is a risk factor for PAD, diabetic microangiopathy and peripheral neuropathy [1]. The involvement of diabetic microangiopathy in leg ulcers is debated [75]. Even in non-ulcerated skin, it has long been discussed whether histopathological changes in diabetes are secondary to PAD or primary to diabetic microangiopathy [76,77,78]. Histopathological patterns that can be associated specifically with diabetic microangiopathy are rare. Capillary thickening in non-ulcerated skin could hint to microangiopathic involvement in wound development, but is not only found in diabetic patients [76]. Fibrin cuffs, as seen in VLUs, have been both found in ischemic and non-ischemic diabetic ulcers [78].

4. Neuropathic Leg Ulcer

Neuropathic ulcers predominantly occur in diabetic patients as a result of peripheral neuropathy leading to insensitivity to pressure or trauma. Ulcerations frequently develop at common pressure points, such as the plantar surface of the foot [79]. Hyperkeratosis in marginal areas is an indispensable characteristic and tends to exceed the size of the underlying epidermal tissue [1,80]. Furthermore, the lesions present with a diffuse and intense inflammatory reaction represented by nodular leukocyte conglomerates. Cellular debris, a degraded extracellular matrix and necrosis can be observed, showing progressive dehydration toward the surface of the ulcer. The dermis is hypertrophic and fibrotic, thereby disrupting the normal structure of the extracellular matrix [80,81] (see Table 6). Impairment of larger blood vessels through wall thickening and capillary cuffs can be present, but it is neither specific nor mandatory [78].

5. Inflammatory Leg Ulcers

5.1. Vasculitis

Vasculitides are heterogeneous diseases that are characterized by primary inflammatory vessel damage, most commonly as a manifestation of a systemic autoimmune process. According to the Chapel Hill classification, they are classified based on the caliber of involved vessels as large-, medium- or small-vessel vasculitis [82]. In this context, ulcerations predominantly occur on the lower extremities and are most often caused by small vessel vasculitis [83]. In particular, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides—granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, and microscopic polyangiitis—are prominent causes of vasculitic leg ulcers, albeit they are relatively rare diseases. However, several other forms, including secondary-type vasculitis, can also induce skin ulceration.
Granulomatosis with polyangiitis (formerly known as Wegener granulomatosis) frequently causes cutaneous lesions. Upon biopsy, there is fibrinoid necrosis of dermal small-vessel walls and nuclear debris. Perivascular inflammatory infiltrates consist of neutrophils, lymphocytes and eosinophils [84,85,86]. However, leukocytoclastic changes, necrotizing granulomatous and unspecific ulcerations, have also been reported [87,88]. A pyoderma gangrenosum-like appearance has also been reported [89,90].
Eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss Syndrome) often affects venules. Diagnosis is supported by numerous eosinophils that can be found in the inflammatory infiltrate, which can also consist of neutrophils, lymphocytes or macrophages [91,92].
In microscopic polyangiitis, tissues show infiltration of the vessel walls by neutrophils, as in leukocytoclastic vasculitis, reaching down into the deep dermis and subcutaneous fat tissue [93].
Cutaneous leukocytoclastic angiitis is one of few entities of single-organ vasculitis [82]. Fibrin deposits in the vessel wall, including strong perivascular neutrophilic infiltrates and cell debris, and extravasated erythrocytes are found regularly [94,95]. It can appear individually or as a cutaneous manifestation of other forms of vasculitis, such as ANCA-associated vasculitis, IgA vasculitis or cryoglobulinemic vasculitis [94]. Thus, the term leukocytoclastic vasculitis may describe the result of heterogeneous pathophysiological processes rather than a distinct entity [96].
Since secondary-type vasculitis can be the result of various heterogeneous diseases, such as infections or neoplasms, specific histopathologic patterns are absent. Small vessels are the most frequently affected, showing perivascular inflammation and fibrinoid necrosis of the vessel wall [97].

5.2. Pyoderma Gangrenosum

Pyoderma gangrenosum (PD) is a very rare inflammatory disease that is characterized by deep necrotic ulcers [98]. The etiology is unknown; however, it is often associated with immune-mediated diseases, such as inflammatory bowel disease and rheumatoid arthritis [99]. The lower leg is the most commonly affected site. However, it can appear on the whole body; operation wounds are also predilected sites [100,101]. Diagnosis is challenging and often delayed, and misdiagnosis is frequent [52,102]. Histopathologic examination reveals dermal neutrophilia, perivascular lymphocytic infiltrate, endothelial swelling and necrosis [103,104,105]. However, histologic findings are non-specific and variable and depend on the clinical stage and the location of the lesion [18,106]. Previous reports have discussed the presence of vasculitis in PD ulcerations as secondary changes [18,107,108] (see Table 7, Figure 5).

5.3. Necrobiosis Lipoidica

Necrobiosis lipoidica is a necrotizing granulomatous inflammatory disease of the skin of unknown etiology, typically appearing on the anterior side of the lower leg [109,110]. The condition has been associated with diabetes mellitus [111]; however, recently, this association has been the subject of scientific research and discussion [112]. Histologically, a palisaded necrobiotic granuloma can be seen, consisting of degenerated bundles of collagen surrounded by histiocytes and multinucleate giant cells, creating an appearance that is sometimes described as “lasagna” or “cake layers” [111,112,113,114,115]. It involves the entire dermis and may extend into the subcutaneous fat resembling panniculitis [112,115]. The area is surrounded by a histiocytic and lymphocytic infiltrate. Focal loss of elastic tissue may also be seen [112,113] (see Table 8).

6. Decubitus

Decubitus ulcers result from soft tissue compression between a bony prominence and an external surface exceeding the capillary pressure for a prolonged period and are thus also referred to as pressure ulcerations. On the lower extremities, they are most frequently located on the heel and malleoli. Clinically, they are classified as grade I–IV [116]. In the general population, their prevalence is low; however, in long-term care settings such as geriatric nursing homes, the reported prevalence reaches 25–41% [2]. In past years, the prevalence has decreased due to pressure-reducing measures and increased mobilization [116]. Biopsies should be considered in nonhealing ulcers after 12 weeks of optimal care [15]. Histopathological analysis of the edges and marginal areas of clinically advanced decubitus ulcers (clinical grade IV) shows heterogenous features that can be summed up in four groups. Type I shows ulcer edema, occluded large blood vessels, degenerated fibroblasts and extensive neutrophils and macrophages. In type II, the surface consists of a fibrin coating and infiltrating neutrophils and macrophages, and the edge contains a considerable number of inflammatory cells. Blood vessels remain open. Type III is characterized by dense fibrinous regions with infiltrating inflammatory cells and remnants of vacuolated fibroblasts in the ulcer edge, and type IV demonstrates a dermal-type structure above a layer of subcutaneous fat. The first shows fat droplets and vacuolated fibroblasts, whereas the latter consists of few fibroblasts and inflammatory cells [117]. The ulcer center changes its appearance depending on the stage of disease. Early wounds exhibit a hemorrhagic crust, a perivascular lymphocytic infiltrate and a diffuse polymorphonuclear cell infiltrate. Healing decubitus ulcers show granulation tissue and edema as well as fibroblast and capillary proliferation. Long-standing, persistent decubitus ulcers are characterized by diffuse fibrosis, coagulation necrosis on the surface and the loss of epidermal appendages [118] (see Table 9).

7. Hydroxyurea-Induced Ulcers

Hydroxyurea is a cytotoxic agent that is commonly used to treat chronic myeloproliferative disorders and acute myeloid leukemia, but it also finds application in other neoplastic diseases as well as in nonproliferative disorders [119]. Hydroxyurea-induced ulcerations are predominantly found in the malleolar region and can often not be distinguished from VLUs macroscopically [120,121]. Histology shows pseudoepitheliomatous hyperplasia, epidermal spongiosis or atrophy in the margin area [119,122,123,124]. Dermal vessels exhibit endothelial cell swelling, thrombotic occlusions and thickening of the vessel walls. Perivascular lymphocytic inflammation with and without leukocytoclastic vasculitis has been reported [119,122,124,125,126]. In later stages, focal hyalinization of blood vessel walls, intraluminal fibrin deposition and dermal fibrosis can be seen, which may resemble the pathologies found in livedoid vasculopathy [119,122,123] (see Table 10).

8. Ulcerating Skin Tumors

Ulcerations stemming from skin and soft tissue tumors, such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma, various cutaneous lymphomas and types of sarcoma, can be the first sign of disease in affected patients [2]. Skin metastases of solid organ tumors can also lead to ulceration [18]. Therefore, when patients present with a long-standing ulceration, a malignant process must be excluded [10]. Histopathological findings ultimately depend on the underlying pathogenesis. Differential diagnosis can often be difficult, as BCC and SCC can both initially present as an ulcer or develop as a secondary lesion in ulcerated or traumatized skin [127,128,129,130,131,132,133,134,135]. Similar reports have also been published for different types of sarcoma and cutaneous lymphomas [136,137,138,139,140].

9. Other Causes

In addition to the diseases described above, leg ulcers can be caused by a plethora of causes. Several hematological and hemostatic disorders; metabolic, autoimmune and dermatologic diseases; genetic diseases; trauma; or adverse drug reactions can cause lower extremity ulcers [1,2]. For instance, Klinefelter’s syndrome (XXY karyotype) is associated with lower leg ulcerations; an increased level of plasminogen activator inhibitor-1 is supposedly involved in its pathogenesis [141,142,143]. At another end of the spectrum, microorganisms and infectious diseases that can lead to direct tissue necrosis include β-hemolytic Streptococcus pyogenes, Staphylococcus aureus, tuberculosis, osteomyelitis and leishmaniosis [1,2].

10. Discussion

Chronic leg ulcers are one of the most common medical problems, affecting up to 5% of the population >65 years of age and posing an increasingly significant public health issue, with treatment costs reaching up to an estimate of USD 96.8 billion in the USA for all chronic wounds and £400–600 million in the UK for VLUs alone [5,144,145]. Therefore, precise and early diagnosis is of high interest. The majority of leg ulcers are of vascular or diabetic origin; however, in developing countries, trauma and infections are more common [146,147].
The differentiation of etiology-specific characteristics and secondary processes in leg ulcers is a diagnostic challenge. Pericapillary fibrin cuffs are non-specific but most frequently seen in VLUs [35,78]. Intraluminal calcium deposits have been described in vascular ulcers irrespective of the underlying pathology in wounds lasting 2 years and longer [80]. Leukocytoclastic vasculitis has been discussed to be concomitant with inflammation, explaining its occurrence in other types of vasculitis, pyoderma gangrenosum or hydroxyurea-induced ulcers [94,96,103,126]. A recent study regarding vasculitis in the marginal area of ulcers of various etiologies detected vasculitis in over 50% of cases, questioning the diagnostic value of the histopathological finding in the diagnosis of ulcer etiology [148]. Some authors even suggested that biopsies obtained from the ulcer bed instead of the recommended edge might lead to a false positive vasculitis diagnosis [95].
Correct sample obtainment is critical for histopathological examination. The biopsy should be performed on the border of the ulcer and should include dermal and hypodermal tissue [95,149,150]. Poor site selection and technique otherwise may frequently lead to a delayed or false diagnosis [151].
Histopathological features discussed in this review aim at reflecting the broad consensus. Nevertheless, certain characteristics remain debated in the expert literature or have not been conclusively investigated. This includes the differential diagnosis between calciphylaxis and the arteriolosclerotic ulcer of Martorell, for example, where the presence of calcium deposits within the lobular fat has been historically used to distinguish both entities, whereas more recent works indicate that the diagnostic value of this finding might be limited [152]. Another example is the histopathological diagnosis of pyoderma gangrenosum, which some authors consider ill advised due to its non-specific inflammatory features [99].
Lower extremity ulcers constitute a major burden on public health. Most ulcers do not require histopathological analysis and can be sufficiently treated based on clinical findings. However, with uncommon or uncommonly appearing ulcers, histopathological findings are critical for the correct diagnosis and also frequently for subsequent treatment. The hallmarks listed in this review might serve as guidance for clinical practice.

Author Contributions

Conceptualization, B.W.; methodology, B.W. and A.G.H.; formal analysis, A.G.H. and J.D.; investigation, A.G.H. and A.O.; writing—original draft preparation, A.G.H.; writing—review and editing, J.D. and A.O.; visualization, A.G.H.; supervision, B.W.; project administration. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

The data used in this review can be shared upon reasonable request to the corresponding author.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Pannier, F.; Rabe, E. Differential diagnosis of leg ulcers. Phlebology 2013, 28 (Suppl. S1), 55–60. [Google Scholar] [CrossRef]
  2. Mekkes, J.; Loots, M.A.M.; Van Der Wal, A.C.; Bos, J.D. Causes, investigation and treatment of leg ulceration. Br. J. Dermatol. 2003, 148, 388–401. [Google Scholar] [CrossRef]
  3. Agale, S.V. Chronic Leg Ulcers: Epidemiology, Aetiopathogenesis, and Management. Ulcers 2013, 2013, 1–9. [Google Scholar] [CrossRef]
  4. Lautenschlager, S.; Eichmann, A. Differential diagnosis of leg ulcers. Curr. Probl. Dermatol. 1999, 27, 259–270. [Google Scholar] [CrossRef] [PubMed]
  5. Sen, C.K.; Gordillo, G.M.; Roy, S.; Kirsner, R.; Lambert, L.; Hunt, T.K.; Gottrup, F.; Gurtner, G.C.; Longaker, M.T. Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair Regen. 2009, 17, 763–771. [Google Scholar] [CrossRef]
  6. Nelzén, O.; Bergqvist, D.; Lindhagen, A. Venous and non-venous leg ulcers: Clinical history and appearance in a population study. Br. J. Surg. 1994, 81, 182–187. [Google Scholar] [CrossRef] [PubMed]
  7. Moffatt, C.J.; Franks, P.J.; Doherty, D.C.; Martin, R.; Blewett, R.; Ross, F. Prevalence of leg ulceration in a London population. QJM Mon. J. Assoc. Physicians 2004, 97, 431–437. [Google Scholar] [CrossRef] [PubMed]
  8. Liedberg, E.; Persson, B.M. Increased incidence of lower limb amputation for arterial occlusive disease. Acta Orthop. Scand. 1983, 54, 230–234. [Google Scholar] [CrossRef] [PubMed]
  9. Bello, Y.M.; Phillips, T.J. Management of venous ulcers. J. Cutan. Med. Surg. 1998, 3 (Suppl. S1), S1-6–12. [Google Scholar]
  10. Labropoulos, N.; Manalo, D.; Patel, N.P.; Tiongson, J.; Pryor, L.; Giannoukas, A.D. Uncommon leg ulcers in the lower extremity. J. Vasc. Surg. 2007, 45, 568–573.e2. [Google Scholar] [CrossRef]
  11. Gottrup, F.; Karlsmark, T. Leg ulcers: Uncommon presentations. Clin. Dermatol. 2005, 23, 601–611. [Google Scholar] [CrossRef]
  12. Körber, A.; Jockenhöfer, F.; Sondermann, W.; Stoffels-Weindorf, M.; Dissemond, J. First manifestation of leg ulcers: Analysis of data from 1000 patients. Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 2017, 68, 483–491. [Google Scholar] [CrossRef]
  13. Isoherranen, K.; O’Brien, J.J.; Barker, J.; Dissemond, J.; Hafner, J.; Jemec, G.B.E.; Kamarachev, J.; Läuchli, S.; Montero, E.C.; Nobbe, S.; et al. Atypical wounds. Best clinical practice and challenges. J. Wound Care 2019, 28 (Suppl. S6), S1–S92. [Google Scholar] [CrossRef]
  14. O’Donnell, T.F.; Passman, M.A.; Marston, W.A.; Ennis, W.J.; Dalsing, M.; Kistner, R.L.; Lurie, F.; Henke, P.K.; Gloviczki, M.L.; Eklöf, B.G.; et al. Management of venous leg ulcers: Clinical practice guidelines of the Society for Vascular Surgery® and the American Venous Forum. J. Vasc. Surg. 2014, 60, 3S–59S. [Google Scholar] [CrossRef]
  15. Bolton, L.L.; Girolami, S.; Corbett, L.; van Rijswijk, L. The Association for the Advancement of Wound Care (AAWC) venous and pressure ulcer guidelines. Ostomy. Wound Manag. 2014, 60, 24–66. [Google Scholar]
  16. Senet, P.; Combemale, P.; Debure, C.; Baudot, N.; Machet, L.; Aout, M.; Vicaut, E.; Lok, C. Angio-Dermatology Group Of The French Society Of Dermatology Malignancy and chronic leg ulcers: The value of systematic wound biopsies: A prospective, multicenter, cross-sectional study. Arch. Dermatol. 2012, 148, 704–708. [Google Scholar] [CrossRef] [PubMed]
  17. Misciali, C.; Dika, E.; Baraldi, C.; Fanti, P.A.; Mirelli, M.; Stella, A.; Bertoncelli, M.; Patrizi, A. Vascular leg ulcers: Histopathologic study of 293 patients. Am. J. Dermatopathol. 2014, 36, 977–983. [Google Scholar] [CrossRef] [PubMed]
  18. Maibach, H.I.; Shai, A. Wound Healing and Ulcers of the Skin; Springer: New York, NY, USA, 2005; ISBN 978-3-540-21275-1. [Google Scholar]
  19. Körber, A.; Schadendorf, D.; Dissemond, J. Causes of leg ulcers. Analysis of the data from a dermatologic wound care center. Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 2009, 60, 483–488. [Google Scholar] [CrossRef] [PubMed]
  20. Evans, C.J.; Fowkes, F.G.; Ruckley, C.V.; Lee, A.J. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J. Epidemiol. Community Health 1999, 53, 149–153. [Google Scholar] [CrossRef] [PubMed]
  21. Fritsch, P.; Schwarz, T. Dermatologie Venerologie: Grundlagen, Klinik, Atlas; 3. Vollständig Überarbeitete Auflage; Springer: Berlin/Heidelberg, Germany, 2018; 1217p, ISBN 978-3-662-53646-9. [Google Scholar]
  22. Eklöf, B.; Rutherford, R.B.; Bergan, J.J.; Carpentier, P.H.; Gloviczki, P.; Kistner, R.L.; Meissner, M.H.; Moneta, G.L.; Myers, K.; Padberg, F.T.; et al. Revision of the CEAP classification for chronic venous disorders: Consensus statement. J. Vasc. Surg. 2004, 40, 1248–1252. [Google Scholar] [CrossRef] [PubMed]
  23. Neumann, H.A.M.; Cornu-Thénard, A.; Jünger, M.; Mosti, G.; Munte, K.; Partsch, H.; Rabe, E.; Ramelet, A.A.; Streit, M. Evidence-based (S3) guidelines for diagnostics and treatment of venous leg ulcers. J. Eur. Acad. Dermatol. Venereol. JEADV 2016, 30, 1843–1875. [Google Scholar] [CrossRef]
  24. Scott, H.J.; Coleridge Smith, P.D.; Scurr, J.H. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br. J. Surg. 1991, 78, 210–211. [Google Scholar] [CrossRef] [PubMed]
  25. Wilkinson, L.S.; Bunker, C.; Edwards, J.C.; Scurr, J.H.; Smith, P.D. Leukocytes: Their role in the etiopathogenesis of skin damage in venous disease. J. Vasc. Surg. 1993, 17, 669–675. [Google Scholar] [CrossRef] [PubMed]
  26. Raffetto, J.D. Pathophysiology of wound healing and alterations in venous leg ulcers-review. Phlebology 2016, 31, 56–62. [Google Scholar] [CrossRef]
  27. Jünger, M.; Steins, A.; Hahn, M.; Häfner, H.M. Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation 2000, 7 Pt 2, S3–S12. [Google Scholar] [CrossRef] [PubMed]
  28. Brem, H.; Stojadinovic, O.; Diegelmann, R.F.; Entero, H.; Lee, B.; Pastar, I.; Golinko, M.; Rosenberg, H.; Tomic-Canic, M. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol. Med. 2007, 13, 30–39. [Google Scholar] [CrossRef]
  29. Herrick, S.E.; Sloan, P.; McGurk, M.; Freak, L.; McCollum, C.N.; Ferguson, M.W. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am. J. Pathol. 1992, 141, 1085–1095. [Google Scholar]
  30. Grey, J.E.; Harding, K.G.; Enoch, S. Venous and arterial leg ulcers. BMJ 2006, 332, 347–350. [Google Scholar] [CrossRef] [PubMed]
  31. Heising, S.; Giebel, J.; Ostrowitzki, A.-L.; Riedel, F.; Haase, H.; Sippel, K.; Jünger, M. Evaluation of apoptotic cells and immunohistochemical detection of FAS, FAS-L, Bcl-2, Bax, p53 and c-Myc in the skin of patients with chronic venous leg ulcers. Int. J. Mol. Med. 2008, 22, 497–505. [Google Scholar] [CrossRef]
  32. Burnand, K.G.; Whimster, I.; Clemenson, G.; Thomas, M.L.; Browse, N.L. The relationship between the number of capillaries in the skin of the venous ulcer-bearing area of the lower leg and the fall in foot vein pressure during exercise. Br. J. Surg. 1981, 68, 297–300. [Google Scholar] [CrossRef]
  33. Falanga, V.; Moosa, H.H.; Nemeth, A.J.; Alstadt, S.P.; Eaglstein, W.H. Dermal pericapillary fibrin in venous disease and venous ulceration. Arch. Dermatol. 1987, 123, 620–623. [Google Scholar] [CrossRef]
  34. Browse, N.L.; Burnand, K.G. The cause of venous ulceration. Lancet Lond. Engl. 1982, 2, 243–245. [Google Scholar] [CrossRef]
  35. Vanscheidt, W.; Laaff, H.; Wokalek, H.; Niedner, R.; Schöpf, E. Pericapillary fibrin cuff: A histological sign of venous leg ulceration. J. Cutan. Pathol. 1990, 17, 266–268. [Google Scholar] [CrossRef]
  36. Fernandez, A.P.; Miteva, M.; Roberts, B.; Ricotti, C.; Rouhani, P.; Romanelli, P. Histopathologic analysis of dermal lymphatic alterations in chronic venous insufficiency ulcers using D2-40. J. Am. Acad. Dermatol. 2011, 64, 1123.e1–1123.e12. [Google Scholar] [CrossRef]
  37. Burg, M.R.; Mitschang, C.; Goerge, T.; Schneider, S.W. Livedoid vasculopathy—A diagnostic and therapeutic challenge. Front. Med. 2022, 9, 1012178. [Google Scholar] [CrossRef] [PubMed]
  38. Goerge, T. Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction. Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 2011, 62, 627–634. [Google Scholar] [CrossRef]
  39. Criado, P.R.; Rivitti, E.A.; Sotto, M.N.; Valente, N.Y.S.; Aoki, V.; Carvalho, J.F.D.; Vasconcellos, C. Livedoid vasculopathy: An intringuing cutaneous disease. An. Bras. Dermatol. 2011, 86, 961–977. [Google Scholar] [CrossRef]
  40. Alavi, A.; Hafner, J.; Dutz, J.P.; Mayer, D.; Sibbald, R.G.; Criado, P.R.; Senet, P.; Callen, J.P.; Phillips, T.J.; Romanelli, M.; et al. Atrophie Blanche: Is It Associated with Venous Disease or Livedoid Vasculopathy? Adv. Skin Wound Care 2014, 27, 518–524. [Google Scholar] [CrossRef] [PubMed]
  41. Gray, H.R.; Graham, J.H.; Johnson, W.; Burgoon, C.F. Atrophie blanche: Periodic painful ulcers of lower extremities. A clinical and histopathological entity. Arch. Dermatol. 1966, 93, 187–193. [Google Scholar] [CrossRef] [PubMed]
  42. Gardette, E.; Moguelet, P.; Bouaziz, J.-D.; Lipsker, D.; Dereure, O.; Le Pelletier, F.; Lok, C.; Maisonobe, T.; Bessis, D.; Conard, J.; et al. Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options. Acta Derm. Venereol. 2018, 98, 842–847. [Google Scholar] [CrossRef] [PubMed]
  43. Kerk, N.; Goerge, T. Livedoid vasculopathy—A thrombotic disease. VASA Z. Gefasskrankheiten 2013, 42, 317–322. [Google Scholar] [CrossRef]
  44. Reagin, H.; Marks, E.; Weis, S.; Susa, J. Livedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease. Am. J. Dermatopathol. 2018, 40, 682–685. [Google Scholar] [CrossRef]
  45. Agirbasli, M.; Göktay, F.; Peker, I.; Gunes, P.; Aker, F.V.; Akkiprik, M. Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions. Cardiovasc. Ther. 2017, 35, e12255. [Google Scholar] [CrossRef]
  46. Becker, A.; Stoffels-Weindorf, M.; Schimming, T.; Dissemond, J. Recurrent leg ulcers due to livedoid vasculopathy: Successful treatment with low-molecular-weight heparin. Dtsch. Med. Wochenschr. 1946 2013, 138, 1458–1462. [Google Scholar] [CrossRef]
  47. Bard, J.W.; Winkelmann, R.K. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch. Dermatol. 1967, 96, 489–499. [Google Scholar] [CrossRef] [PubMed]
  48. Krishna, S.M.; Moxon, J.V.; Golledge, J. A review of the pathophysiology and potential biomarkers for peripheral artery disease. Int. J. Mol. Sci. 2015, 16, 11294–11322. [Google Scholar] [CrossRef] [PubMed]
  49. Hardman, R.L.; Jazaeri, O.; Yi, J.; Smith, M.; Gupta, R. Overview of classification systems in peripheral artery disease. Semin. Interv. Radiol. 2014, 31, 378–388. [Google Scholar] [CrossRef] [PubMed]
  50. Foley, T.R.; Armstrong, E.J.; Waldo, S.W. Contemporary evaluation and management of lower extremity peripheral artery disease. Heart Br. Card. Soc. 2016, 102, 1436–1441. [Google Scholar] [CrossRef] [PubMed]
  51. Sieggreen, M.Y.; Kline, R.A. Arterial insufficiency and ulceration: Diagnosis and treatment options. Adv. Skin Wound Care 2004, 17, 242–251. [Google Scholar] [CrossRef]
  52. Hafner, J.; Nobbe, S.; Partsch, H.; Läuchli, S.; Mayer, D.; Amann-Vesti, B.; Speich, R.; Schmid, C.; Burg, G.; French, L.E. Martorell hypertensive ischemic leg ulcer: A model of ischemic subcutaneous arteriolosclerosis. Arch. Dermatol. 2010, 146, 961–968. [Google Scholar] [CrossRef]
  53. Ong, S.; Coulson, I.H. Normo-renal calciphylaxis: Response to sodium thiosulfate. J. Am. Acad. Dermatol. 2011, 64, e82–e84. [Google Scholar] [CrossRef]
  54. Weber, B.; Deinsberger, J.; Hafner, J.; Beltraminelli, H.; Tzaneva, S.; Böhler, K. Localization-mapping of arteriolosclerotic ulcers of Martorell using two-dimensional computational rendering reveals a predominant location on the mid-lateral lower leg. J. Eur. Acad. Dermatol. Venereol. 2020, 35. [Google Scholar] [CrossRef]
  55. Martorell, F. Leg ulcers hypertonicum. Med. Klin. 1957, 52, 1945–1946. [Google Scholar]
  56. Hines, E.A.; Farber, E.M. Ulcer of the leg due to arteriolosclerosis and ischemia, occurring in the presence of hypertensive disease (hypertensive-ischemic ulcers). Proc. Staff Meet. Mayo Clin. 1946, 21, 337–346. [Google Scholar]
  57. Vuerstaek, J.D.D.; Reeder, S.W.I.; Henquet, C.J.M.; Neumann, H.A.M. Arteriolosclerotic ulcer of Martorell. J. Eur. Acad. Dermatol. Venereol. JEADV 2010, 24, 867–874. [Google Scholar] [CrossRef]
  58. Hafner, J. Calciphylaxis and Martorell Hypertensive Ischemic Leg Ulcer: Same Pattern—One Pathophysiology. Dermatology 2016, 232, 523–533. [Google Scholar] [CrossRef] [PubMed]
  59. Dagregorio, G.; Guillet, G. A retrospective review of 20 hypertensive leg ulcers treated with mesh skin grafts. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 166–169. [Google Scholar] [CrossRef]
  60. Pinto, A.P.F.L.; Silva, N.A., Jr.; Osorio, C.T.; Rivera, L.M.; Carneiro, S.; Ramos-e-Silva, M.; Bica, B.E.R.G. Martorell’s Ulcer: Diagnostic and Therapeutic Challenge. Case Rep. Dermatol. 2015, 7, 199–206. [Google Scholar] [CrossRef] [PubMed]
  61. De Andrés, J.; Villanueva, V.L.; Mazzinari, G.; Fabregat, G.; Asensio, J.M.; Monsalve, V. Use of a Spinal Cord Stimulator for Treatment of Martorell Hypertensive Ulcer. Reg. Anesth. Pain Med. 2011, 36, 83–86. [Google Scholar] [CrossRef]
  62. Giot, J.-P.; Paris, I.; Levillain, P.; Huguier, V.; Charreau, S.; Delwail, A.; Garcia, M.; Garnier, J.; Bernard, F.-X.; Dagregorio, G.; et al. Involvement of IL-1 and Oncostatin M in Acanthosis Associated With Hypertensive Leg Ulcer. Am. J. Pathol. 2013, 182, 806–818. [Google Scholar] [CrossRef] [PubMed]
  63. Vuerstaek, J.D. Reply. J. Vasc. Surg. 2007, 46, 615–616. [Google Scholar] [CrossRef]
  64. Leu, H.J. Hypertensive ischemic leg ulcer (Martorell’s ulcer): A specific disease entity? Int. Angiol. J. Int. Union Angiol. 1992, 11, 132–136. [Google Scholar]
  65. Kuiper, J.P.; Brakkee, A.J. Skin blood flow measurement in microangiopathic changes. Z. Hautkr. 1985, 60, 1495–1496, 1501–1505. [Google Scholar]
  66. Henderson, C.A.; Highet, A.S.; Lane, S.A.; Hall, R. Arterial hypertension causing leg ulcers. Clin. Exp. Dermatol. 1995, 20, 107–114. [Google Scholar] [CrossRef]
  67. Salcido, R.S. Enduring eponyms: The mystery of the Martorell ulcer. Adv. Skin Wound Care 2012, 25, 535. [Google Scholar] [CrossRef]
  68. Monfort, J.-B.; Cury, K.; Moguelet, P.; Chasset, F.; Bachmeyer, C.; Francès, C.; Barbaud, A.; Senet, P. Cutaneous Arteriolosclerosis Is Not Specific to Ischemic Hypertensive Leg Ulcers. Dermatology 2018, 234, 194–197. [Google Scholar] [CrossRef] [PubMed]
  69. Hayashi, M. Calciphylaxis: Diagnosis and clinical features. Clin. Exp. Nephrol. 2013, 17, 498–503. [Google Scholar] [CrossRef] [PubMed]
  70. Jiménez-Gallo, D.; Ossorio-García, L.; Linares-Barrios, M. Calcinosis Cutis and Calciphylaxis. Actas Dermosifiliogr. 2015, 106, 785–794. [Google Scholar] [CrossRef] [PubMed]
  71. Nigwekar, S.U.; Wolf, M.; Sterns, R.H.; Hix, J.K. Calciphylaxis from nonuremic causes: A systematic review. Clin. J. Am. Soc. Nephrol. CJASN 2008, 3, 1139–1143. [Google Scholar] [CrossRef]
  72. Sowers, K.M.; Hayden, M.R. Calcific uremic arteriolopathy: Pathophysiology, reactive oxygen species and therapeutic approaches. Oxid. Med. Cell. Longev. 2010, 3, 109–121. [Google Scholar] [CrossRef] [PubMed]
  73. Aihara, S.; Yamada, S.; Uchida, Y.; Arase, H.; Tsuchimoto, A.; Nakano, T.; Taniguchi, M.; Higashi, H.; Kitazono, T.; Tsuruya, K. The Successful Treatment of Calciphylaxis with Sodium Thiosulfate and Hyperbaric Oxygen in a Non-dialyzed Patient with Chronic Kidney Disease. Intern. Med. 2016, 55, 1899–1905. [Google Scholar] [CrossRef] [PubMed]
  74. Colboc, H.; Moguelet, P.; Bazin, D.; Carvalho, P.; Dillies, A.-S.; Chaby, G.; Maillard, H.; Kottler, D.; Goujon, E.; Jurus, C.; et al. Localization, Morphologic Features, and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy. JAMA Dermatol. 2019, 155, 789. [Google Scholar] [CrossRef] [PubMed]
  75. LoGerfo, F.W.; Coffman, J.D. Current concepts. Vascular and microvascular disease of the foot in diabetes. Implications for foot care. N. Engl. J. Med. 1984, 311, 1615–1619. [Google Scholar] [CrossRef]
  76. dos Santos, V.P.; Caffaro, R.A.; Pozzan, G.; Saieg, M.A.; Castelli Júnior, V. Comparative histological study of atherosclerotic lesions and microvascular changes in amputated lower limbs of diabetic and non-diabetic patients. Arq. Bras. Endocrinol. Metabol. 2008, 52, 1115–1123. [Google Scholar] [CrossRef] [PubMed]
  77. Goldenberg, S.; Alex, M.; Joshi, R.A.; Blumenthal, H.T. Nonatheromatous peripheral vascular disease of the lower extremity in diabetes mellitus. Diabetes 1959, 8, 261–273. [Google Scholar] [CrossRef]
  78. Ferguson, M.W.J.; Herrick, S.E.; Spencer, M.-J.; Shaw, J.E.; Boulton, A.J.M.; Sloan, P. The Histology of Diabetic Foot Ulcers. Diabet. Med. 1996, 13, S30–S33. [Google Scholar] [CrossRef]
  79. Bowling, F.L.; Reeves, N.D.; Boulton, A.J. Gait-related strategies for the prevention of plantar ulcer development in the high risk foot. Curr. Diabetes Rev. 2011, 7, 159–163. [Google Scholar] [CrossRef]
  80. Piaggesi, A.; Viacava, P.; Rizzo, L.; Naccarato, G.; Baccetti, F.; Romanelli, M.; Zampa, V.; Del Prato, S. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: Effects of pressure relief. Diabetes Care 2003, 26, 3123–3128. [Google Scholar] [CrossRef]
  81. Fahey, T.J.; Sadaty, A.; Jones, W.G.; Barber, A.; Smoller, B.; Shires, G.T. Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 1991, 50, 308–313. [Google Scholar] [CrossRef] [PubMed]
  82. Jennette, J.C.; Falk, R.J.; Bacon, P.A.; Basu, N.; Cid, M.C.; Ferrario, F.; Flores-Suarez, L.F.; Gross, W.L.; Guillevin, L.; Hagen, E.C.; et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65, 1–11. [Google Scholar] [CrossRef] [PubMed]
  83. Lotti, T.; Ghersetich, I.; Comacchi, C.; Jorizzo, J.L. Cutaneous small-vessel vasculitis. J. Am. Acad. Dermatol. 1998, 39, 667–687, quiz 688–690. [Google Scholar] [CrossRef] [PubMed]
  84. Marzano, A.V.; Balice, Y.; Papini, M.; Testa, R.; Berti, E.; Crosti, C. Localized Wegener’s granulomatosis: Localized WG. J. Eur. Acad. Dermatol. Venereol. 2011, 25, 1466–1470. [Google Scholar] [CrossRef] [PubMed]
  85. Nasir, N.; Ali, S.A.; Mehmood Riaz, H.M. Cutaneous Ulcers as Initial Presentation of Localized Granulomatosis with Polyangiitis: A Case Report and Review of the Literature. Case Rep. Rheumatol. 2015, 2015, 1–7. [Google Scholar] [CrossRef]
  86. Tashtoush, B.; Memarpour, R.; Johnston, Y.; Ramirez, J. Large pyoderma gangrenosum-like ulcers: A rare presentation of granulomatosis with polyangiitis. Case Rep. Rheumatol. 2014, 2014, 850364. [Google Scholar] [CrossRef]
  87. Daoud, M.S.; Gibson, L.E.; DeRemee, R.A.; Specks, U.; el-Azhary, R.A.; Daniel Su, W.P. Cutaneous Wegener’s granulomatosis: Clinical, histopathologic, and immunopathologic features of thirty patients. J. Am. Acad. Dermatol. 1994, 31, 605–612. [Google Scholar] [CrossRef]
  88. Barksdale, S.K.; Hallahan, C.W.; Kerr, G.S.; Fauci, A.S.; Stern, J.B.; Travis, W.D. Cutaneous pathology in Wegener’s granulomatosis. A clinicopathologic study of 75 biopsies in 46 patients. Am. J. Surg. Pathol. 1995, 19, 161–172. [Google Scholar] [CrossRef] [PubMed]
  89. Boudny, C.; Nievergelt, H.; Braathen, L.R.; Simon, D. Wegener’s granulomatosis presenting as pyoderma gangrenosum. J. Dtsch. Dermatol. Ges. J. Ger. Soc. Dermatol. JDDG 2008, 6, 477–479. [Google Scholar] [CrossRef]
  90. Genovese, G.; Tavecchio, S.; Berti, E.; Rongioletti, F.; Marzano, A.V. Pyoderma gangrenosum-like ulcerations in granulomatosis with polyangiitis: Two cases and literature review. Rheumatol. Int. 2018, 38, 1139–1151. [Google Scholar] [CrossRef]
  91. Marzano, A.V.; Vezzoli, P.; Berti, E. Skin involvement in cutaneous and systemic vasculitis. Autoimmun. Rev. 2013, 12, 467–476. [Google Scholar] [CrossRef]
  92. Marzano, A.V.; Raimondo, M.G.; Berti, E.; Meroni, P.L.; Ingegnoli, F. Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis. Clin. Rev. Allergy Immunol. 2017, 53, 428–438. [Google Scholar] [CrossRef]
  93. Kawakami, T.; Soma, Y.; Saito, C.; Ogawa, H.; Nagahuchi, Y.; Okazaki, T.; Ozaki, S.; Mizoguchi, M. Cutaneous manifestations in patients with microscopic polyangiitis: Two case reports and a minireview. Acta Derm. Venereol. 2006, 86, 144–147. [Google Scholar] [CrossRef]
  94. Höfler, G.; Kreipe, H.H.; Moch, H. Pathologie: Das Lehrbuch: Mit 1.300 Meist Farbigen Abbildungen und rund 150 Tabellen; Elsevier: Amsterdam, The Netherlands, 2019; ISBN 978-3-437-42390-1. [Google Scholar]
  95. Carlson, J.A. The histological assessment of cutaneous vasculitis. Histopathology 2010, 56, 3–23. [Google Scholar] [CrossRef]
  96. Frumholtz, L.; Laurent-Roussel, S.; Lipsker, D.; Terrier, B. Cutaneous Vasculitis: Review on Diagnosis and Clinicopathologic Correlations. Clin. Rev. Allergy Immunol. 2020, 61, 181–193. Available online: http://link.springer.com/10.1007/s12016-020-08788-4 (accessed on 21 November 2020). [CrossRef]
  97. Carlson, J.A.; Chen, K.-R. Cutaneous vasculitis update: Small vessel neutrophilic vasculitis syndromes. Am. J. Dermatopathol. 2006, 28, 486–506. [Google Scholar] [CrossRef]
  98. Brooklyn, T.; Dunnill, G.; Probert, C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006, 333, 181–184. [Google Scholar] [CrossRef] [PubMed]
  99. Ruocco, E.; Sangiuliano, S.; Gravina, A.; Miranda, A.; Nicoletti, G. Pyoderma gangrenosum: An updated review. J. Eur. Acad. Dermatol. Venereol. 2009, 23, 1008–1017. [Google Scholar] [CrossRef] [PubMed]
  100. Gameiro, A.; Pereira, N.; Cardoso, J.C.; Gonçalo, M. Pyoderma gangrenosum: Challenges and solutions. Clin. Cosmet. Investig. Dermatol. 2015, 8, 285–293. [Google Scholar] [CrossRef] [PubMed]
  101. Foessleitner, P.; Just, U.; Kiss, H.; Farr, A. Challenge of diagnosing pyoderma gangrenosum after caesarean section. BMJ Case Rep. 2019, 12, e230315. [Google Scholar] [CrossRef] [PubMed]
  102. Weenig, R.H.; Davis, M.D.P.; Dahl, P.R.; Su, W.P.D. Skin Ulcers Misdiagnosed as Pyoderma Gangrenosum. N. Engl. J. Med. 2002, 347, 1412–1418. [Google Scholar] [CrossRef] [PubMed]
  103. Su, W.P.; Schroeter, A.L.; Perry, H.O.; Powell, F.C. Histopathologic and immunopathologic study of pyoderma gangrenosum. J. Cutan. Pathol. 1986, 13, 323–330. [Google Scholar] [CrossRef]
  104. Bhat, R.M. Pyoderma gangrenosum: An update. Indian Dermatol. Online J. 2012, 3, 7–13. [Google Scholar] [CrossRef]
  105. Elder, D.E. (Ed.) Lever’s Histopathology of the Skin, 11th ed.; Wolters Kluwer: Philadelphia, PA, USA, 2015; ISBN 978-1-4511-9037-3. [Google Scholar]
  106. Schwaegerle, S.M.; Bergfeld, W.F.; Senitzer, D.; Tidrick, R.T. Pyoderma gangrenosum: A review. J. Am. Acad. Dermatol. 1988, 18, 559–568. [Google Scholar] [CrossRef] [PubMed]
  107. English, J.S.C.; Fenton, D.A.; Barth, J.; Gray, W.; Wilkinson, J.D. Pyoderma gangrenosum and leucocytoclastic vasculitis in association with rheumatoid arthritis-a report of two cases. Clin. Exp. Dermatol. 1984, 9, 270–276. [Google Scholar] [CrossRef] [PubMed]
  108. Wong, E.; Greaves, M.W. Pyoderma gangrenosum and leucocytoclastic vasculitis. Clin. Exp. Dermatol. 1985, 10, 68–72. [Google Scholar] [CrossRef] [PubMed]
  109. Sibbald, C.; Reid, S.; Alavi, A. Necrobiosis Lipoidica. Dermatol. Clin. 2015, 33, 343–360. [Google Scholar] [CrossRef]
  110. Tee, S.-I.; Chen, Q.P.; Lim, Y.L. Necrobiosis Lipoidica With Elastophagocytosis on an Unusual Location. Am. J. Dermatopathol. 2014, 36, 741–743. [Google Scholar] [CrossRef]
  111. Muller, S.A.; Winkelmann, R.K. Necrobiosis lipoidica diabeticorum. A clinical and pathological investigation of 171 cases. Arch. Dermatol. 1966, 93, 272–281. [Google Scholar] [CrossRef]
  112. Lepe, K.; Riley, C.A.; Salazar, F.J. Necrobiosis lipoidica. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2020. Available online: http://www.ncbi.nlm.nih.gov/books/NBK459318/ (accessed on 19 October 2020).
  113. Calonje, J.E.; Brenn, T.; Lazar, A.J.; McKee, P.H. Pathology of the Skin; Elsevier Health Sciences UK: London, UK, 2011; Available online: http://www.myilibrary.com?id=756554 (accessed on 19 October 2020).
  114. Eason, C.R.; Stovall, C.; Corley, S.B. Ulcerated indurated plaques on the upper extremities. JAAD Case Rep. 2019, 5, 749–751. [Google Scholar] [CrossRef]
  115. Yen, P.-S.; Wang, K.-H.; Chen, W.-Y.; Yang, Y.-W.; Ho, W.-T. The many faces of necrobiosis lipoidica: A report of three cases with histologic variations. Dermatol. Sin. 2011, 29, 67–71. [Google Scholar] [CrossRef]
  116. Anders, J.; Heinemann, A.; Leffmann, C.; Leutenegger, M.; Pröfener, F.; von Renteln-Kruse, W. Decubitus ulcers: Pathophysiology and primary prevention. Dtsch. Arzteblatt Int. 2010, 107, 371–381, quiz 382. [Google Scholar] [CrossRef]
  117. Vandeberg, J. Pressure (decubitus) ulcer: Variation in histopathology?A light and electron microscope study*1. Hum. Pathol. 1995, 26, 195–200. [Google Scholar] [CrossRef]
  118. Witkowski, J.A.; Parish, L.C. Histopathology of the decubitus ulcer. J. Am. Acad. Dermatol. 1982, 6, 1014–1021. [Google Scholar] [CrossRef]
  119. Best, P.J. Hydroxyurea-Induced Leg Ulceration in 14 Patients. Ann. Intern. Med. 1998, 128, 29. [Google Scholar] [CrossRef]
  120. Dissemond, J.; Körber, A. Hydroxyurea-induced ulcers on the leg. CMAJ Can. Med. Assoc. J. J. Assoc. Medicale Can. 2009, 180, 1132. [Google Scholar] [CrossRef]
  121. Goerge, T.; Schellong, G.; Mesters, R.M.; Berdel, W.E. Mimicry of hydroxyurea-induced leg ulcer by distal vena saphena parva insufficiency. Ann. Hematol. 2012, 91, 471–472. [Google Scholar] [CrossRef]
  122. Sirieix, M.-E.; Debure, C.; Baudot, N.; Dubertret, L.; Roux, M.-E.; Morel, P.; Frances, C.; Loubeyres, S.; Beylot, C.; Lambert, D.; et al. Leg Ulcers and Hydroxyurea: Forty-one Cases. Arch. Dermatol. 1999, 135, 818–820. Available online: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/archderm.135.7.818 (accessed on 20 October 2020). [CrossRef]
  123. Kato, N.; Kimura, K.; Yasukawa, K.; Yoshida, K. Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: A case report and review of the literature. J. Dermatol. 1999, 26, 56–62. [Google Scholar] [CrossRef] [PubMed]
  124. Quattrone, F.; Dini, V.; Barbanera, S.; Zerbinati, N.; Romanelli, M. Cutaneous ulcers associated with hydroxyurea therapy. J. Tissue Viability 2013, 22, 112–121. [Google Scholar] [CrossRef] [PubMed]
  125. Daoud, M.S.; Gibson, L.E.; Pittelkow, M.R. Hydroxyurea dermopathy: A unique lichenoid eruption complicating long-term therapy with hydroxyurea. J. Am. Acad. Dermatol. 1997, 36 Pt 1, 178–182. [Google Scholar] [CrossRef] [PubMed]
  126. Stahl, R.L.; Silber, R. Vasculitic leg ulcers in chronic myelogenous leukemia. Am. J. Med. 1985, 78, 869–872. [Google Scholar] [CrossRef] [PubMed]
  127. Harris, B.; Eaglstein, W.H.; Falanga, V. Basal cell carcinoma arising in venous ulcers and mimicking granulation tissue. J. Dermatol. Surg. Oncol. 1993, 19, 150–152. [Google Scholar] [CrossRef]
  128. Phillips, T.J.; Salman, S.M.; Rogers, G.S. Nonhealing leg ulcers: A manifestation of basal cell carcinoma. J. Am. Acad. Dermatol. 1991, 25 Pt 1, 47–49. [Google Scholar] [CrossRef] [PubMed]
  129. Blank, A.A.; Schnyder, U.W. Squamous cell carcinoma and basal cell carcinoma within the clinical picture of a chronic venous insufficiency in the third stage. Dermatologica 1990, 181, 248–250. [Google Scholar] [CrossRef] [PubMed]
  130. Lanehart, W.H.; Sanusi, I.D.; Misra, R.P.; O’Neal, B. Metastasizing basal cell carcinoma originating in a stasis ulcer in a black woman. Arch. Dermatol. 1983, 119, 587–591. [Google Scholar] [CrossRef] [PubMed]
  131. Steffen, C. Marjolin’s ulcer. Report of two cases and evidence that Marjolin did not describe cancer arising in scars of burns. Am. J. Dermatopathol. 1984, 6, 187–193. [Google Scholar] [CrossRef]
  132. Simmons, M.A.; Edwards, J.M.; Nigam, A. Marjolin’s ulcer presenting in the neck. J. Laryngol. Otol. 2000, 114, 980–982. [Google Scholar] [CrossRef]
  133. Riess, C. Neoplastic ulcus cruris. Spinocellular carcinoma of the left lower leg with lymph node metastases of the popliteal, inguinal and iliac areas. Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 1989, 40, 592–593. [Google Scholar]
  134. Tchanque-Fossuo, C.N.; Millsop, J.W.; Johnson, M.A.; Dahle, S.E.; Isseroff, R.R. Ulcerated Basal Cell Carcinomas Masquerading as Venous Leg Ulcers. Adv. Skin Wound Care 2018, 31, 130–134. [Google Scholar] [CrossRef]
  135. Snyder, R.J.; Stillman, R.M.; Weiss, S.D. Epidermoid cancers that masquerade as venous ulcer disease. Ostomy. Wound Manag. 2003, 49, 63–66. [Google Scholar]
  136. Johnson, E.L.; Pierpont, Y.N.; Donate, G.; Hiro, M.H.; Mannari, R.J.; Strickland, T.J.; Robson, M.C.; Payne, W.G. Clinical challenge: Cutaneous Kaposi’s sarcoma of the lower extremity. Int. Wound J. 2011, 8, 163–168. [Google Scholar] [CrossRef]
  137. Boyce, D.E. Non-Hodgkins lymphoma masquerading as a chronic venous leg ulcer. Br. J. Plast. Surg. 1998, 51, 487. [Google Scholar] [CrossRef]
  138. González-Vela, M.C.; González-López, M.A.; Val-Bernal, J.F.; Mayorga, M.; Armesto, S.; Fernández-Llaca, H. Cutaneous diffuse large B-cell lymphoma of the leg mimicking a chronic venous ulcer. Eur. J. Dermatol. EJD 2007, 17, 92–93. [Google Scholar] [PubMed]
  139. Garbea, A.; Dippel, E.; Hildenbrand, R.; Bleyl, U.; Schadendorf, D.; Goerdt, S. Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br. J. Dermatol. 2002, 146, 144–147. [Google Scholar] [CrossRef] [PubMed]
  140. Kamal, W.S.A.; Affandi, A.M.; Bhullar, A.; Kamal, W.S.Z. Relapsed lymphoma mimicking venous ulcer: A case report. Med. J. Malays. 2018, 73, 253–254. [Google Scholar]
  141. De Morentin, H.M.; Dodiuk-Gad, R.P.; Brenner, S. Klinefelter’s syndrome presenting with leg ulcers. Skinmed 2004, 3, 274–278. [Google Scholar] [CrossRef] [PubMed]
  142. Shanmugam, V.K.; Tsagaris, K.C.; Attinger, C.E. Leg ulcers associated with Klinefelter’s syndrome: A case report and review of the literature. Int. Wound J. 2012, 9, 104–107. [Google Scholar] [CrossRef] [PubMed]
  143. Zollner, T.M.; Veraart, J.C.; Wolter, M.; Hesse, S.; Villemur, B.; Wenke, A.; Werner, R.J.; Boehncke, W.H.; Jost, S.S.; Scharrer, I.; et al. Leg ulcers in Klinefelter’s syndrome—Further evidence for an involvement of plasminogen activator inhibitor-1. Br. J. Dermatol. 1997, 136, 341–344. [Google Scholar] [PubMed]
  144. Sen, C.K. Human Wounds and Its Burden: An Updated Compendium of Estimates. Adv. Wound Care 2019, 8, 39–48. [Google Scholar] [CrossRef]
  145. Simka, M.; Majewski, E. The Social and Economic Burden of Venous Leg Ulcers: Focus on the Role of Micronized Purified Flavonoid Fraction Adjuvant Therapy. Am. J. Clin. Dermatol. 2003, 4, 573–581. [Google Scholar] [CrossRef]
  146. Fu, X.; Sheng, Z.; Cherry, G.W.; Li, Q. Epidemiological study of chronic dermal ulcers in China. Wound Repair Regen. 1998, 6, 21–27. [Google Scholar] [CrossRef]
  147. Zeegelaar, J.E.; Stroïnk, A.C.; Steketee, W.H.; Faber, W.R.; van der Wal, A.C.; Komolafe, I.O.O.; Dzamalala, C.; Chibwana, C.; Wendte, J.F.; Zijlstra, E.E. Etiology and incidence of chronic ulcers in Blantyre, Malawi. Int. J. Dermatol. 2006, 45, 933–936. [Google Scholar] [CrossRef] [PubMed]
  148. Gonzalez, C.D.; Florell, S.R.; Bowen, A.R.; Presson, A.P.; Petersen, M.J. Histopathologic vasculitis from the periulcer edge: A retrospective cohort study. J. Am. Acad. Dermatol. 2019, 81, 1353–1357. [Google Scholar] [CrossRef] [PubMed]
  149. Izadi, K.; Ganchi, P. Chronic wounds. Clin. Plast. Surg. 2005, 32, 209–222. [Google Scholar] [CrossRef]
  150. Janowska, A.; Dini, V.; Oranges, T.; Iannone, M.; Loggini, B.; Romanelli, M. Atypical Ulcers: Diagnosis and Management. Clin. Interv. Aging 2019, 14, 2137–2143. [Google Scholar] [CrossRef]
  151. Elston, D.M.; Stratman, E.J.; Miller, S.J. Skin biopsy. J. Am. Acad. Dermatol. 2016, 74, 1–16. [Google Scholar] [CrossRef]
  152. Deinsberger, J.; Sirovina, S.; Bromberger, S.; Böhler, K.; Vychytil, A.; Meier-Schiesser, B.; Petzelbauer, P.; Beltraminelli, H.; Hafner, J.; Weber, B. Microstructural comparative analysis of calcification patterns in calciphylaxis versus arteriolosclerotic ulcer of Martorell. Eur. J. Dermatol. 2021, 31, 705–711. [Google Scholar] [CrossRef]
Dermatopathology 11 00007 g001
Figure 1. Leg ulcer caused by chronic venous disease. (A) Overview, red arrow = beginning of ulceration, black asterisk = inflammatory infiltrates, blue asterisk = erythrocyte extravasate, black circle = diffuse edema. (B) Magnification, black arrows = hemosiderophages, black rectangle = fibrin cuff.
Figure 1. Leg ulcer caused by chronic venous disease. (A) Overview, red arrow = beginning of ulceration, black asterisk = inflammatory infiltrates, blue asterisk = erythrocyte extravasate, black circle = diffuse edema. (B) Magnification, black arrows = hemosiderophages, black rectangle = fibrin cuff.
Dermatopathology 11 00007 g001
Dermatopathology 11 00007 g002
Figure 2. Ulcer caused by livedoid vasculopathy. (A) Overview, black rectangle = epidermal atrophy, white rectangle = diffuse leukocyte infiltration. (B) Magnification, black arrows = leukocytes.
Figure 2. Ulcer caused by livedoid vasculopathy. (A) Overview, black rectangle = epidermal atrophy, white rectangle = diffuse leukocyte infiltration. (B) Magnification, black arrows = leukocytes.
Dermatopathology 11 00007 g002
Dermatopathology 11 00007 g003
Figure 3. Arteriolosclerotic ulcer of Martorell. (A) Black rectangles = calcification. (B) Black rectangle = subintimal hyalinization.
Figure 3. Arteriolosclerotic ulcer of Martorell. (A) Black rectangles = calcification. (B) Black rectangle = subintimal hyalinization.
Dermatopathology 11 00007 g003
Dermatopathology 11 00007 g004
Figure 4. Calciphylaxis. (A) Overview, black rectangles = calcifications in different layers of the skin. (B) Magnification, black rectangle = vessel-associated calcifications, black arrows = extra-arterial calcium deposits.
Figure 4. Calciphylaxis. (A) Overview, black rectangles = calcifications in different layers of the skin. (B) Magnification, black rectangle = vessel-associated calcifications, black arrows = extra-arterial calcium deposits.
Dermatopathology 11 00007 g004
Dermatopathology 11 00007 g005
Figure 5. Pyoderma gangrenosum. (A) Overview, black rectangle = massive leukocyte infiltration. (B) Magnification, yellow asterisks = leukocyte infiltration, black rectangles = perivascular lymphocytic infiltrates with associated fibrin thrombi suggestive of secondary vasculitis.
Figure 5. Pyoderma gangrenosum. (A) Overview, black rectangle = massive leukocyte infiltration. (B) Magnification, yellow asterisks = leukocyte infiltration, black rectangles = perivascular lymphocytic infiltrates with associated fibrin thrombi suggestive of secondary vasculitis.
Dermatopathology 11 00007 g005
Table 1. Venous leg ulcer characteristics.
Table 1. Venous leg ulcer characteristics.
Venous Leg Ulcer
LocationMalleoli, pretibial
SpecificsLate chronic venous disease
EpidermisSpongiosis
Hyperkeratosis
Acanthosis
DermisInflammatory cell infiltration
Diffuse edema
Hemosiderophages
Dermal sclerosis
Fibrosis
Collagen bundle degeneration
HypodermisLipodermatosclerosis
VesselsFibrin cuffs
Reduced capillary density
Dilated capillaries
Erythrocyte extravasation
Ectatic lymph vessels
Table 2. Livedoid vasculopathy characteristics.
Table 2. Livedoid vasculopathy characteristics.
Livedoid Vasculopathy
LocationBilateral
SpecificsWhite scars
EpidermisSpongiosis
Atrophy
DermisSecondary inflammatory changes
Subpapillary plexus thrombosis
VesselsEndothelial edema
Wall thickening
Fibrin thrombi
Subintimal hyalinization
Table 3. Arterial-ischemic leg ulcer characteristics.
Table 3. Arterial-ischemic leg ulcer characteristics.
Arterial-Ischemic Leg Ulcer
LocationToes, plantar
SpecificsDemarcated lesions
EpidermisNecrosis
Epidermal thinning
DermisSclerosis
Necrosis
VesselsThrombosis
Table 4. Arteriolosclerotic ulcer of Martorell characteristics.
Table 4. Arteriolosclerotic ulcer of Martorell characteristics.
Arteriolosclerotic Ulcer of Martorell
LocationLateral, lower leg
SpecificsDisproportional pain
EpidermisNecrosis
Acanthosis
DermisNecrosis
VesselsMedia hypertrophy
Stenosis
Calcification
Sub-endothelial hyalinosis
Thrombosis
Subintimal hyalinization
Table 5. Calciphylaxis characteristics.
Table 5. Calciphylaxis characteristics.
Calciphylaxis
LocationLower leg
SpecificsDisproportional pain
EpidermisNecrosis
DermisNecrosis
Calcium deposits
HypodermisDiffuse calcification
VesselsFibrosis
Intima hyperplasia
Media calcification
Thrombosis
Table 6. Neuropathic leg ulcer characteristics.
Table 6. Neuropathic leg ulcer characteristics.
Neuropathic Leg Ulcer
LocationPlantar
SpecificsDiabetes-associated
EpidermisHyperkeratosis
Epidermal thinning
DermisLeukocyte infiltration
Degraded extracellular matrix
Cellular debris
Fibrosis
Necrosis
VesselsWall thickening
Table 7. Pyoderma gangrenosum characteristics. PVLI = Perivascular lymphocytic infiltrate.
Table 7. Pyoderma gangrenosum characteristics. PVLI = Perivascular lymphocytic infiltrate.
Pyoderma Gangrenosum
LocationLower leg
SpecificsDeep necrotic ulcers
EpidermisNecrosis
DermisNeutrophil infiltration
VesselsPVLI
Endothelial swelling
Secondary vasculitis
Table 8. Necrobiosis lipoidica characteristics.
Table 8. Necrobiosis lipoidica characteristics.
Necrobiosis Lipoidica
LocationAnterior, lower leg
Specifics“Layered” histology
EpidermisNecrosis
DermisDegenerated collagen
Histiocytes
Multinucleated giant cells
Leukocyte infiltration
Table 9. Decubitus characteristics. PVLI = Perivascular lymphocytic infiltrate.
Table 9. Decubitus characteristics. PVLI = Perivascular lymphocytic infiltrate.
Decubitus
LocationHeel, malleoli
SpecificsHistology type-dependent
Epidermis-
DermisFibrosis
Leukocyte infiltration
Atypical fibroblasts
Edema
VesselsPVLI
Occlusion
Table 10. Hydroxyurea-induced ulcer characteristics. PVLI = Perivascular lymphocytic infiltrate.
Table 10. Hydroxyurea-induced ulcer characteristics. PVLI = Perivascular lymphocytic infiltrate.
Hydroxyurea-Induced Ulcers
LocationMalleoli
SpecificsAfter hydroxyurea administration
EpidermisSpongiosis
Atrophy
Hyperplasia
DermisFibrosis
VesselsEndothelial edema
Wall thickening
Thrombosis
PVLI
Secondary vasculitis
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hofmann, A.G.; Deinsberger, J.; Oszwald, A.; Weber, B. The Histopathology of Leg Ulcers. Dermatopathology 2024, 11, 62-78. https://doi.org/10.3390/dermatopathology11010007

AMA Style

Hofmann AG, Deinsberger J, Oszwald A, Weber B. The Histopathology of Leg Ulcers. Dermatopathology. 2024; 11(1):62-78. https://doi.org/10.3390/dermatopathology11010007

Chicago/Turabian Style

Hofmann, Amun Georg, Julia Deinsberger, André Oszwald, and Benedikt Weber. 2024. "The Histopathology of Leg Ulcers" Dermatopathology 11, no. 1: 62-78. https://doi.org/10.3390/dermatopathology11010007

APA Style

Hofmann, A. G., Deinsberger, J., Oszwald, A., & Weber, B. (2024). The Histopathology of Leg Ulcers. Dermatopathology, 11(1), 62-78. https://doi.org/10.3390/dermatopathology11010007

Article Metrics

Back to TopTop